Back to Search
Start Over
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
- Source :
- Tolstrup, L K, Bastholt, L, Zwisler, A D O, Dieperink, K B & Pappot, H 2019, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Journal of patient-reported outcomes, vol. 3, 19 . https://doi.org/10.1186/s41687-019-0111-8, Journal of Patient-Reported Outcomes, Tolstrup, L K, Bastholt, L, Zwisler, A D, Dieperink, K B & Pappot, H 2019, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Journal of Patient-Reported Outcomes, vol. 3, 19 . https://doi.org/10.1186/s41687-019-0111-8, Tolstrup, L K, Bastholt, L, Dieperink, K B, Zwisler, A D O & Pappot, H 2018, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Multinational Association of Supportive Care in Cancer, Wien, Austria, 27/06/2018-30/06/2018 ., University of Southern Denmark, Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-7 (2019)
- Publication Year :
- 2019
-
Abstract
- CONTEXT: Toxicity-monitoring plays an important role in all cancer treatment, however, early recognition is vital for detecting and treating immune-related symptoms. Preparing a Patient Reported Outcomes tool and including melanoma patients receiving immunotherapy in the reporting of symptoms, may optimize toxicity-monitoring.OBJECTIVES: The objective of this study was to identify the symptoms and their equivalent questions to include from the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) library for melanoma patients, receiving immunotherapy and, further, to evaluate if all relevant symptoms are covered by this tool.METHODS: To establish the relevant symptoms, three measures were taken. First, a literature search was carried out in three databases. Second, a chart audit was performed including medical records from melanoma patients receiving immunotherapy. Finally, the product information for the relevant immunotherapies was studied.RESULTS: Ten articles were included as a result of the literature search. As for the chart audit, a total of 37 patients (48 treatments with immunotherapy) were included. Overall, the reported symptoms from the literature review aligned with those identified in the chart audit. The examination of the product information supported the findings from review and chart audit, revealing only one additional symptom. In total, 28 PRO-CTCAE symptoms were selected comprising of 56 PRO-questions plus an additional question on blood in stool.CONCLUSION: When preparing a Patient Reported Outcomes tool it is important that the preparatory work of selecting questions is done properly. By going through the literature, performing a chart audit, and examining the product information, the most important and relevant symptoms have been uncovered, facilitating the design of a PROquestionnaire, based on PRO-CTCAE, that fits the patient population under investigation.
- Subjects :
- medicine.medical_specialty
Metastatic melanoma
medicine.medical_treatment
Short Report
Health Informatics
PRO-CTCAE
03 medical and health sciences
0302 clinical medicine
Health Information Management
medicine
Symptomatic toxicity
Intensive care medicine
Adverse effect
Melanoma
Patient-reported outcomes
business.industry
lcsh:Public aspects of medicine
030503 health policy & services
Medical record
lcsh:RA1-1270
Common Terminology Criteria for Adverse Events
Immunotherapy
Cancer treatment
Patient population
030220 oncology & carcinogenesis
Adverse events
Chart audit
0305 other medical science
business
Item-selection
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Tolstrup, L K, Bastholt, L, Zwisler, A D O, Dieperink, K B & Pappot, H 2019, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Journal of patient-reported outcomes, vol. 3, 19 . https://doi.org/10.1186/s41687-019-0111-8, Journal of Patient-Reported Outcomes, Tolstrup, L K, Bastholt, L, Zwisler, A D, Dieperink, K B & Pappot, H 2019, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Journal of Patient-Reported Outcomes, vol. 3, 19 . https://doi.org/10.1186/s41687-019-0111-8, Tolstrup, L K, Bastholt, L, Dieperink, K B, Zwisler, A D O & Pappot, H 2018, ' Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy ', Multinational Association of Supportive Care in Cancer, Wien, Austria, 27/06/2018-30/06/2018 ., University of Southern Denmark, Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-7 (2019)
- Accession number :
- edsair.doi.dedup.....6ea6c5f4fc58a6f7c91672e717a8696b
- Full Text :
- https://doi.org/10.1186/s41687-019-0111-8